Identification of metabolic biomarkers in patients with type 2 diabetic coronary heart diseases based on metabolomic approach

Abstract

Type 2 diabetic coronary heart disease (T2DM-CHD) is a kind of serious and complex disease. Great attention has been paid to exploring its mechanism; however, the detailed understanding of T2DM-CHD is still limited. Plasma samples from 15 healthy controls, 13 coronary heart disease (CHD) patients, 15 type 2 diabetes mellitus (T2DM) patients and 28 T2DM-CHD patients were analyzed in this research. The potential biomarkers of CHD and T2DM were detected and screened out by 1H NMR-based plasma metabolic profiling and multivariate data analysis. About 11 and 12 representative metabolites of CHD and T2DM were identified respectively, mainly including alanine, arginine, proline, glutamine, creatinine and acetate. Then the diagnostic model was further constructed based on the previous metabolites of CHD and T2DM to detect T2DM-CHD with satisfying sensitivity of 92.9%, specificity of 93.3% and accuracy of 93.2%, validating the robustness of 1H NMR-based plasma metabolic profiling to diagnostic strategy. The results demonstrated that the NMR-based metabolomics approach processed good performance to identify diagnostic plasma biomarkers and most identified metabolites related to T2DM and CHD could be considered as predictors of T2DM-CHD as well as the therapeutic targets for prevention, which provided new insight into diagnosing and forecasting of complex diseases.

Recent Advances in NMR-Based Metabolomics

“…In another study, plasma from a total of 71 patients with diabetes, coronary heart disease, diabetic coronary heart disease, or healthy controls were investigated to evaluate the metabolic risk for diabetic coronary heart disease. 122 Interestingly, the diagnostic model constructed based on the metabolites detected diabetic coronary heart disease with 93% sensitivity and 93% specificity. It is known that obesity is a major risk factor for diabetes.…”

Metabolite biomarkers of type 2 diabetes mellitus and pre-diabetes: a systematic review and meta-analysis

“…It is critical to study of bring data on the appearance of metabolic profile abnormalities before the occurrence of pre-diabetes or T2DM, since this might predict and allow prevent the disease progression to pre-diabetes or T2DM. However, there is no current consensus regarding the use of metabolites as diagnostic biomarkers of T2DM, and part of the results were from clinical single-center or insufficient consideration of mixed factors such as different regions and different populations [ 11 ]. Therefore, it is a need for an effective and comprehensive evaluation method for the use of metabolites as diagnostic biomarkers of pre-diabetes or early T2DM.…”

Metabolomic profiling of blood plasma in patients with primary brain tumours: Basal plasma metabolites correlated with tumour grade and plasma biomarker analysis predicts feasibility of the successful statistical discrimination from healthy subjects – a preliminary study

“… As metabolomics covers the relatively small size of the number of endogenous molecules related to the number of genes, RNA species or proteins, it is obvious that in the identification of potential low molecular biomarkers some overlap between different pathologies can occur. As an example, two of the metabolites (glucose and creatinine) identified in this study potentially able to act as plasma biomarkers have been proposed as potential biomarkers in type 2 diabetes . It is of interest because advanced cancer is accompanied by hyperglycaemia.…”